Navigation Links
AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
Date:8/11/2009

other 2,952 2,207 4,092 4,013 ------------------------------------------------------------------------- 8,379 10,457 14,490 20,205 ------------------------------------------------------------------------- Operating expenses Cost of sales 4,545 4,758 8,239 9,362 Research and development costs, net of tax credits and grants 12,076 17,345 23,513 31,034 Selling, general and administrative 3,102 6,606 6,656 11,010 Depreciation and amortization Property, plant and equipment 331 397 642 766 Intangible assets 563 876 1,120 1,716 ------------------------------------------------------------------------- 20,617 29,982 40,170 53,888 ------------------------------------------------------------------------- Loss from operations (12,238) (19,525) (25,680) (33,683) ------------------------------------------------------------------------- Other income (expenses) Interest income 118 311 274 588 Interest expense - (53) (2) (68) Foreign exchange (loss) gain (960) (502) (60) 1,753 Loss on disposal of long-lived assets held for sale - (810) - (35) ------------------------------------------------------------------------- (842) (1,054) 212 2,238 ------------------------------------------------------------------------- Net loss for the period (13,080) (20,579) (25,468) (31,445) ---------
'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Mass. , June 2, 2015 /PRNewswire/ ... a biotechnology company focused on discovering and ... of dermatology and ophthalmology, today announced that Dr. ... Officer, will present at the 23 rd ... six-day world congress will include in-depth presentations ...
(Date:6/2/2015)... 02, 2015 Through rare discovery of ... Yancy Corporation is enabling World Scientists to actually ... biological sample, displaying the full nature (position, shape, size, ... , Jeff Porter, Co-Founder of the Yancy Corporation, says, ... – rare. They come once in a lifetime, if ...
(Date:6/1/2015)... 02, 2015 Chosen for his ... Jack Uldrich has been selected as keynote speaker ... today. He will deliver his keynote: "Don't Stop ... delivered presentations to the American Medical Association, Blue ... Neurology, Alcetel-Lucent/Verizon Forum on Wireless Healthcare, United Healthcare, ...
(Date:6/1/2015)... RARITAN, N.J. , June 1, ... announced data from the Phase 3 multicenter study ... survival (PFS) with trabectedin (YONDELIS ® ) compared ... or leiomyosarcoma (LMS) previously treated with an anthracycline ... is the largest randomized Phase 3 study ever ...
Breaking Biology Technology:RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 3RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 4Scientists Eying Rare Discovery Of New Physics & Light Microscope Technology 2Futurist Jack Uldrich to Address the Future of Pharmaceuticals 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6
... Madison, Wis. - Quintessence Biosciences , a ... one of its EVade cancer treatments, has been selected ... ,Quintessence said that pending a favorable preclinical safety assessment, ... Drug Administration an investigational new drug application in ...
... adison, Wis. - Five years removed from ... investors and questioning the value of the online world, ... The models are both progressive in their cutting-edge approach ... realities. , ,The picture of those business models ...
... - If you dropped the word sustainability in ... of them would have pegged you as an aging ... riding their bikes to work. , ,Today, sustainability still ... might stick around to talk because there's no avoiding ...
Cached Biology Technology:Web-centric entrepreneurs find models that attract investment 2Web-centric entrepreneurs find models that attract investment 3Web-centric entrepreneurs find models that attract investment 4Web-centric entrepreneurs find models that attract investment 5Re-engineering our economy to be sustainable and profitable 2Re-engineering our economy to be sustainable and profitable 3Re-engineering our economy to be sustainable and profitable 4
(Date:5/28/2015)... ALLEN, Va. , May 28, 2015 /PRNewswire/ ... the release of a new report titled "Markets ... materials (reversible polymers, inorganic capsule and vascular systems, ... coatings) will grow to around $2.7 billion by ... deliverable from n-tech,s extensive coverage of smart materials. Other ...
(Date:5/22/2015)... , May 22, 2015 ... Market by Solution (2D, 3D, Thermal, Emotion, Forensic), by Software ... User (Government and Utilities, Consumer and Home) - Global ... to grow from $2.77 Billion in 2015 to $6.19 ... Browse 79 market data Tables and   ...
(Date:5/19/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
Breaking Biology News(10 mins):The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... In the perilous hours immediately after birth, a newborn ... from its mother. Under normal circumstances, newborns mount a ... This survival response involves a process of controlled breakdown ... has been well documented, the key mechanistic regulators of ...
... University today announced the discovery of an underlying genetic cause ... infancy that also affects millions of adults around the world ... were just published in PLoS ONE , a professional ... to this frustrating syndrome, which is difficult to treat and ...
... frequently causes gastric ulcers and is also one of the ... infection is also associated with another gastric cancer risk factor, ... Clinical Investigation , researchers led by Richard Peek at Vanderbilt ... -induced gastric cancer. Peek and colleagues found that low iron ...
Cached Biology News:Nutrient-sensing enzymes key to starvation response and survival in newborn mammals 2Researchers discover genetic basis for eczema, new avenue to therapies 2Ironing out the link between H. pylori infection and gastric cancer 2
... polyclonal to JMJD2D ( Abpromise for ... Synthetic peptide conjugated to KLH derived ... Human JMJD2D.(Note: the amino acid sequence is ... Entrez Gene ID: 55693 ...
Rabbit polyclonal to JAK1 (phospho Y1022 + Y1023) ( Abpromise for all tested applications). entrezGeneID: 3716 SwissProtID: P23458...
Cytofix/Cytoperm Plus Kit with GolgiPlug 250 Tests...
The BD PhosFlow Fix Buffer I can be used for the simultaneous fixation and permeabilization of cells prior to intracellular staining. Applications: Intracellular Staining (Flow) Storage Temperature:...
Biology Products: